New cell therapy takes on tough leukemia
NCT ID NCT07026942
First seen Nov 12, 2025 · Last updated May 23, 2026 · Updated 24 times
Summary
This study tests a new treatment for acute myeloid leukemia (AML) that has returned or not responded to standard therapy. It uses specially engineered immune cells from a healthy donor to target and kill cancer cells. The trial has two phases: first to find the safest dose, then to see how well it works. About 42 participants will receive chemotherapy followed by one or two infusions of these cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY AML are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.